These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31165068)

  • 1. Physical Vein Models to Quantify the Flow Performance of Sclerosing Foams.
    Bottaro E; Paterson J; Zhang X; Hill M; Patel VA; Jones SA; Lewis AL; Millar TM; Carugo D
    Front Bioeng Biotechnol; 2019; 7():109. PubMed ID: 31165068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Foam-in-Vein: Characterisation of Blood Displacement Efficacy of Liquid Sclerosing Foams.
    Meghdadi A; Jones SA; Patel VA; Lewis AL; Millar TM; Carugo D
    Biomolecules; 2022 Nov; 12(12):. PubMed ID: 36551153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of clinically-relevant parameters on the cohesiveness of sclerosing foams in a biomimetic vein model.
    Carugo D; Ankrett DN; O'Byrne V; Wright DD; Lewis AL; Hill M; Zhang X
    J Mater Sci Mater Med; 2015 Nov; 26(11):258. PubMed ID: 26449448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterisation and optimisation of foams for varicose vein sclerotherapy.
    Roberts TG; Cox SJ; Lewis AL; Jones SA
    Biorheology; 2020; 57(2-4):77-85. PubMed ID: 33459690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results.
    Hamel-Desnos C; Desnos P; Wollmann JC; Ouvry P; Mako S; Allaert FA
    Dermatol Surg; 2003 Dec; 29(12):1170-5; discussion 1175. PubMed ID: 14725657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits of polidocanol endovenous microfoam (Varithena®) compared with physician-compounded foams.
    Carugo D; Ankrett DN; Zhao X; Zhang X; Hill M; O'Byrne V; Hoad J; Arif M; Wright DD; Lewis AL
    Phlebology; 2016 May; 31(4):283-95. PubMed ID: 26036246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel developments in foam sclerotherapy: Focus on Varithena® (polidocanol endovenous microfoam) in the management of varicose veins.
    Star P; Connor DE; Parsi K
    Phlebology; 2018 Apr; 33(3):150-162. PubMed ID: 28166694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Size of Sclerosing Foams Prepared by Ultrasound, Mechanical Agitation, and the Handmade Tessari Method for Treatment of Varicose Veins.
    Critello CD; Fiorillo AS; Matula TJ
    J Ultrasound Med; 2017 Mar; 36(3):649-658. PubMed ID: 28127790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The history of sclerosing foams.
    Wollmann JC
    Dermatol Surg; 2004 May; 30(5):694-703; discussion 703. PubMed ID: 15099310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and ex vivo evaluation of the biological performance of sclerosing foams.
    Bottaro E; Paterson JAJ; Quercia L; Zhang X; Hill M; Patel VA; Jones SA; Lewis AL; Millar TM; Carugo D
    Sci Rep; 2019 Jul; 9(1):9880. PubMed ID: 31285447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Saphenous ablation: sclerosant or sclerofoam?
    Coleridge Smith P
    Semin Vasc Surg; 2005 Mar; 18(1):19-24. PubMed ID: 15791549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Technical feasibility and early results of radiologically guided foam sclerotherapy for treatment of varicose veins.
    Li L; Hong XY; Zeng XQ; Luo PL; Yi Q
    Dermatol Surg; 2011 Jul; 37(7):992-8. PubMed ID: 21585599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel biomimetic analysis system for quantitative characterisation of sclerosing foams used for the treatment of varicose veins.
    Carugo D; Ankrett DN; O'Byrne V; Willis S; Wright DD; Lewis AL; Hill M; Zhang X
    J Mater Sci Mater Med; 2013 Jun; 24(6):1417-23. PubMed ID: 23512153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of sulodexide on stability of sclerosing foams.
    Critello CD; Fiorillo AS; Cristiano MC; de Franciscis S; Serra R
    Phlebology; 2019 Apr; 34(3):191-200. PubMed ID: 29871533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Properties of polidocanol foam in view of its use in sclerotherapy.
    Nastasa V; Samaras K; Ampatzidis Ch; Karapantsios TD; Trelles MA; Moreno-Moraga J; Smarandache A; Pascu ML
    Int J Pharm; 2015 Jan; 478(2):588-96. PubMed ID: 25433198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venous disorders: treatment with sclerosant foam.
    Bergan J; Pascarella L; Mekenas L
    J Cardiovasc Surg (Torino); 2006 Feb; 47(1):9-18. PubMed ID: 16434941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sclerotherapy: a study comparing polidocanol in foam and liquid form.
    Uncu H
    Phlebology; 2010 Feb; 25(1):44-9. PubMed ID: 20118346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sclerosing foam in the treatment of varicose veins and telangiectases: history and analysis of safety and complications.
    Frullini A; Cavezzi A
    Dermatol Surg; 2002 Jan; 28(1):11-5. PubMed ID: 11991262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of ultrasound-guided foam sclerotherapy for recurrent varicose veins: immediate results.
    Kakkos SK; Bountouroglou DG; Azzam M; Kalodiki E; Daskalopoulos M; Geroulakos G
    J Endovasc Ther; 2006 Jun; 13(3):357-64. PubMed ID: 16784324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary experience with a new sclerosing foam in the treatment of varicose veins.
    Tessari L; Cavezzi A; Frullini A
    Dermatol Surg; 2001 Jan; 27(1):58-60. PubMed ID: 11231246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.